KAKEN PHARMACEUTICAL CO.,LTD.(4521) News

Announcement of the Result of Phase III Clinical Trial of KP-001 in Japan

[Summary] Consolidated Financial Results for the Six-Months Period of Fiscal 2025 (Six-Month Period Ended September 30, 2025) [JGAAP]

KAKEN PHARMA, First Half Ordinary Profit Decreases by 97%, Jul-Sep Ordinary Profit Decreases by 99%

Revision to Consolidated Earnings Forecast for the Fiscal Year Ending March 31, 2026

KAKEN PHARMA, Ordinary Profit Forecast for the Fiscal Year Revised Downward by 53%

Approval for Marketing Authorization for Efinaconazole in Germany for the Treatment of Onychomycosis

Approval for Marketing Authorization for ECCLOCK gel 5% in Korea for Treatment of Primary Axillary Hyperhidrosis

[Summary] Consolidated Financial Results for the Three Months Period of Fiscal 2025 (Three Month Period Ended June 30, 2025) [JGAAP]

Strategic Collaboration with Astria Therapeutics, Inc. to Develop and Commercialize Navenibart for Hereditary Angioedema in Japan

KAKEN PHARMA, Apr-Jun (1Q) Ordinary Profit Decreases by 86%

License Agreement for “gMSC1”, the Allogenic Synovial Mesenchymal Stem Cell-Derived Three-Dimensional Artificial Tissue

Notice of Implementation of Share Benefit Rules and Disposal of Treasury Stock by Third-Party Allotment

Notice Regarding Completion of Cancellation of Treasury Shares

[Summary]Consolidated Financial Results for the Fiscal Year Ended March 31, 2025 [JGAAP]

Notice Regarding Differences Between Non-Consolidated Financial Results and Results for the Previous Fiscal Year

Updates on Actions to Implement Management that is Conscious of Cost of Capital and Stock Price

KAKEN PHARMA, 72% Decrease in Ordinary Profit for The Current Fiscal Year

Notice Regarding Completion of Acquisition of Treasury Shares

Partnership and License Agreement for the Commercialization of Sebetralstat for Hereditary Angioedema in Japan

Partial Revision of Long-Term Business Plan 2031